首页> 外文期刊>Schizophrenia research >The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.
【24h】

The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.

机译:在评估精神分裂症和精神分裂症门诊患者的抗精神病药物依从性时,简短依从性评定量表(BARS)在电子监测中得到了验证。

获取原文
获取原文并翻译 | 示例
           

摘要

Among outpatients with schizophrenia, antipsychotic non-adherence is common, grossly under-detected by patients and their prescribers, and is associated with poor clinical outcomes. Using electronic monitoring (EM) as the reference standard we evaluated the reliability and validity as well as the sensitivity and specificity of a recently developed, brief, pencil-paper, clinician-administered adherence instrument [the Brief Adherence Rating Scale (BARS)] to assess the oral antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. EM and BARS adherence and symptom severity ratings were gathered at baseline and prospectively at 6 monthly visits in 61 participants (n=35 with schizophrenia; n=26 with schizoaffective disorder). A significant positive relationship was found between mean BARS and EM adherence (beta=0.98; rs=0.59, p<0.0001). Cronbach's coefficient alpha revealed very high internal reliability for the BARS (alpha=0.92). A moderate-to-strong degree of test-retest reliability was also found for the BARS (beta ranged from 0.53 to 0.92 and rs ranged from 0.46 to 0.86). Regarding concurrent validity of the BARS, greater mean BARS adherence was significantly related to lower mean PANSS total scores (beta=-0.40; rs=-0.39, p=0.002) and to lower mean Positive symptom sub-scale scores (beta=-0.08, p=.007; rs=-0.28, p=.02). An initial 3-month monitoring period with the BARS also demonstrated good sensitivity (73%) and specificity (74%) in identifying non-adherent outpatients (defined as <70% mean EM adherence). Relative to EM, the BARS appears to provide valid, reliable, sensitive, and specific estimates of antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. The BARS appears to be a promising candidate as a brief adherence assessment instrument for feasible use in community-based settings.
机译:在精神分裂症的门诊患者中,抗精神病药物的非依从性很普遍,患者及其开处方者的检测严重不足,并且与临床效果差有关。使用电子监测(EM)作为参考标准,我们评估了最近开发的,简短的,铅笔纸,临床医生管理的依从性工具[简短依从性评定量表(BARS)]的可靠性和有效性以及敏感性和特异性评估精神分裂症和精神分裂症门诊患者口服抗精神病药物的依从性。 EM和BARS依从性和症状严重程度评分是在基线时收集的,前瞻性是在61位参与者中进行了6个月的随访(n = 35精神分裂症; n = 26分裂情感障碍)。在平均BARS与EM依从性之间发现显着正相关(β= 0.98; rs = 0.59,p <0.0001)。 Cronbach系数α显示BARS的内部可靠性很高(α= 0.92)。还发现BARS的重测信度为中度到重度(β范围从0.53至0.92,rs范围从0.46至0.86)。关于BARS的并发有效性,更高的平均BARS依从性与较低的PANSS总平均分(β= -0.40; rs = -0.39,p = 0.002)和较低的阳性症状子量表平均分(beta = -0.08)显着相关。 ,p = .007; rs = -0.28,p = .02)。 BARS的最初3个月监测期在识别非依从性门诊患者(定义为<70%的平均EM依从性)方面也显示出良好的敏感性(73%)和特异性(74%)。相对于EM,BAR似乎为精神分裂症和精神分裂症门诊患者的抗精神病药物依从性提供了有效,可靠,敏感和具体的估计。作为在社区环境中可行使用的简短依从性评估工具,BAR似乎是有希望的候选人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号